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Abstract: The lentiviral accessory protein, Vpx, is known to counteract a restriction factor 
that is specific to myeloid cells, such as macrophages and dendritic cells. This review 
summarizes the findings in two seminal studies that identify SAMHD1 as the cellular 
protein that is responsible for myeloid cell restriction, and establish the existence of other 
types of restriction in these cells. 
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1. Introduction  
The Genus “Lentivirus” includes viruses that infect mammals including primates, sheep, goats, 
cattle, horses and cats. Lentivirus infection has typically been associated with slow diseases affecting 
the immune system. Lentiviruses have complex genomes encoding multiple “accessory” genes in 
addition to the prototypical retroviral structural genes, gag, pol and env. Lentiviral accessory genes 
were initially found to be largely dispensable for virus replication in vitro. However, over the years, 
multiple biological roles have emerged for these genes, and their roles in in vivo viral replication and 
pathogenesis are increasingly becoming clear. Collectively, lentiviral accessory genes play multiple 
roles in regulating the relationship between the virus and the host and, more specifically, many of the 
encoded proteins specialize in overcoming innate immune defense mechanisms [1]. The host proteins 
that are effectors for these innate immune mechanisms are often referred to as “restriction factors”. 
Lentiviruses are also well known for their unusual ability to infect non-dividing cells, such as 
myeloid-lineage cells. Thus, many lentiviruses have the ability to infect macrophages and/or dendritic 
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cells. These cells are thought to play crucial roles in establishment of infection at mucosal sites, 
dissemination of virus throughout the body and, specifically lymphoid organs and the central nervous 
system, and to facilitate trans-infection of T-cells (reviewed in [2]). 
Primate lentiviruses naturally infect African primates. So far, 40 African primate species have 
been  documented by serology to harbor lentiviruses, and 32 of those instances are confirmed by 
sequencing [3]. All primate lentiviruses encode an accessory gene termed vpr (viral protein, 
regulatory). Viruses in the phylogenetic group that includes SIVsm, HIV-2 and SIVmac contain two 
homologous genes, vpr and its paralog, vpx (Figure 1). It has been proposed that vpr and vpx in these 
viruses arose through duplication of an ancestral vpr gene [4]. This duplication would likely have 
occurred shortly after the HIV-1/SIVcpz and the SIVsmm/HIV-2 lineages diverged [4]. Because the 
SIVsmm/HIV-2 vpx genes appear to be more closely related to SIVagm vpr than they are to HIV-1 
vpr, other investigators have proposed that vpx arose as the result of a recombination event that 
brought vpr sequences from SIVagm into SIVsmm, followed by a period of fast, adaptive evolution [5].  
Figure 1. Genetic structure of HIV-1 and SIVsmm/SIVmac/HIV-2. 
 
 
Vpr alleles from all tested lineages of primate lentiviruses share the ability to induce arrest in the G2 
phase of the cell cycle [6–11], followed by apoptosis [12,13]. Vpx, however, has no effect on the cell 
cycle and, instead, is required for efficient infection of myeloid cells, such as macrophages and 
dendritic cells [8,14–16]. Vpx appears to promote the accumulation of full-length viral DNA in 
non-dividing cells [8,17–20]. To explain the ability of Vpx to enhance lentiviral infection of myeloid 
cells, Goujon et al. proposed that Vpx overcomes a restriction factor [17]. Treatment with proteasome 
inhibitors had a similar effect to that of Vpx expression, which led to the model that the restriction 
mechanism involved the ubiquitin/proteasome system [17].  
Restriction factors are invariably genetically dominant. In agreement with that, fusion of permissive 
cells (i.e., infection of which does not require Vpx) with restricting ones led to heterokaryons that had 
the restricting phenotype [19]. Another property of some restriction factors is that their activity is 
saturable (reviewed in [1]). Pre-delivery of Vpx protein into myeloid cells via SIV virions or virus-like 
particles (VLP) prior to infection dramatically enhanced the permissivity of myeloid cells to infection 
by either SIV or HIV-1 [19–22]. However, preincubation of target cells with either VLPs encoding 
no  Vpx or encoding inactive mutants of Vpx did not render cells more susceptible to subsequent Viruses 2011, 3                  
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infection  [22,23], even if VLPs were used at high multiplicities of infection [24]. Therefore, 
the available evidence indicates that the myeloid cell-specific restriction, presumably SAMHD1, is 
not saturable.  
Despite the divergent functions of Vpr and Vpx, these proteins share their ability to bind and, 
presumably, manipulate the Cul4A
DDB1/DCAF1 ubiquitin ligase (reviewed in [25]). Binding of lentiviral 
Vpr and Vpx proteins to DCAF1 is mediated by a highly conserved leucine-rich motif [26]. While the 
association with Cul4A
DDB1/DCAF1 ubiquitin ligase was clearly required for Vpr to induce G2 arrest, the 
role of Vpx associating with the same ubiquitin ligase was, initially, unclear (reviewed in [25,27]). 
Two reports in 2008 demonstrated that the interaction of Vpx with DCAF1 is required for the 
enhancement of infectivity of myeloid cells [19,20]. These studies showed that depletion of DCAF1 
via RNA interference overcame the restriction effect [19,20] and that expression of a Vpx mutant, 
Q76A, devoid of DCAF1 binding ability [20] was inactive. 
HIV-1, a virus that does not encode Vpx, infects MDM (although with relatively low efficiency) 
and fails to infect DC. However, when pre-loaded with Vpx protein (via VLPs, for example) both 
MDM and DC become exquisitely sensitive to infection by HIV-1 [19–21]. Therefore, not only does 
Vpx overcome a restriction against cognate viruses (SIVsmm/SIVmac/HIV-2), but it also allows 
HIV-1 to infect DC, and to more efficiently infect MDM. Furthermore, inclusion of the Vpx protein 
HIV-1 particles enhanced infectivity of myeloid cells [28]. These observations demonstrated that a 
previously unrecognized restriction against HIV-1 exists in myeloid cells, although no activity in 
HIV-1 appears to have evolved against such a restriction. 
Most cell lines fail to recapitulate the restriction that is observed in myeloid cells. One notable 
exception to that is the Thp-1 monocytoid line, which after differentiation in response to PMA 
stimulation, acquires macrophage-like properties. Differentiated Thp-1 cells restrict HIV-1 and 
SIVmac in a manner that is overcome by ectopic expression of Vpx [17,22].  
2. Identification of SAMHD1 as the Vpx-Sensitive Restriction Factor  
Recently, two groups have identified the culprit restriction factor that is overcome by Vpx as being 
the sterile alpha motif (SAM) and HD domain-containing protein-1 protein (SAMHD1) [29,30].  
Laguette and coworkers established a stable transfectant of Thp-1 expressing SIVmac251 Vpx so 
that large numbers of cells expressing Vpx and the presumed restriction factor could be isolated. Cells 
were induced to differentiate, and extracts were prepared, and tandem-affinity purified using FLAG 
and HA tags on Vpx. Silver-stained bands on SDS-PAGE revealed the presence of multiple bands, 
which were identified via tandem mass spectrometry. Suspect bands included Vpx, components of the 
Cul4A
DDB1/DCAF1 ubiquitin ligase complex and SAMHD1 [30]. 
The isolation of SAMHD1 by Hrecka and co-workers [29] followed a slightly different method. 
Hrecka et al. took advantage of the known requirement of the Cul4 complex for the function of Vpx, 
and transfected the major subunits of that complex (Cul4, DDB1 and DCAF1), along with SIVmac239 
Vpx, into 293T cells. This is particularly remarkable given that SAMHD1-mediated restriction does 
not work in this cell line. Epitope tags for tandem affinity purification were place on distal members of 
the complex, specifically HA-Cul4 and FLAG-Vpx so that (a) partial complexes would not be purified; 
and (b) complexes containing DCAF subunits other than DCAF1 would also not be purified.  Viruses 2011, 3                  
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Both research teams, using different methods as well as different cell types, produced the same hit, 
SAMHD1, as the candidate protein for the long-sought myeloid restriction factor. The expected 
properties of SAMHD1 in the context of Vpx restriction were confirmed as follows. First, both groups 
showed that Vpx induced proteolytic degradation of SAMHD1, which was overcome by incubation by 
proteasome inhibitors. Regarding the specific role that the Cul4/DDB1/DCAF1 complex is thought to 
have in degradation, both groups tested the role of Q76 Vpx residue, mutation of which was earlier 
shown to be unable to bind to DCAF1 [26] and not to be able to enforce restriction [20]. As expected, 
Vpx Q76A mutants in either SIVmac251 [30] or SIVmac239 [29] failed to induce degradation of 
SAMHD1. Hrecka et al. more specifically probed the role of Cul4A
DDB1/DCAF1 by performing RNAi 
experiments in MDM, targeting DCAF1. These experiments showed that depletion of DCAF1 in 
MDM abolished Vpx’s ability to induce degradation of SAMHD1 [29]. A model describing the 
manipulation of Cul4A
DDB1/DCAF1 by Vpx is presented in Figure 2. 
Figure 2. Proposed model for the ubiquitin ligase complex responsible for putative 
ubiquitination of SAMHD1. Adapted from [25].  
 
 
SAMHD1 expression correlates with the ability or inability of various cell types to restrict, with 
some exceptions (see below). Thus, SAMHD1 is highly expressed in restricting cell types, such as 
Thp-1, monocytes, monocyte-derived macrophages (MDM) and monocyte-derived dendritic cells 
(MDDC) and is undetectable (by Western blot) in permissive ones, such as Jurkat, SupT1, HPV-ALL 
and U937 [30]. However, as pointed out by Hrecka and co-workers, this correlation is far from 
perfect [29]. This is exemplified by the observation that certain cell types, such as undifferentiated 
Thp-1 and 293T, which are unable to restrict, do express SAMHD1 [29]. Therefore, the presence or 
absence of SAMHD1 alone fails to completely explain the restriction of HIV-1 and SIV in myeloid 
cells, and therefore one anticipates that the story will get even more interesting as additional 
requirements, perhaps cellular co-factors, come to light. 
The Vpr and Vpx family of accessory proteins is conserved in sequence but functionally diverse. To 
confirm whether the newly discovered ability of Vpx to induce degradation of SAMHD1 correlated 
with the known functional abilities of various alleles to overcome restriction in myeloid cells, both 
Laguette et al. and Hrecka et al. tested a variety of such alleles [29,30]. In summary, vpx alleles from Viruses 2011, 3                  
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SIVmac251, HIV-2ROD, and SIVmac239 induced degradation of SAMHD1 and overcame myeloid 
restriction to HIV-1 [29,30]. In contrast, vpx from two different isolates of SIVrcm from Gabon and 
Nigeria, or from HIV-1 vpr failed to instigate degradation of SAMHD1 [29,30]. 
Because Vpx induces degradation of SAMHD1, depletion via RNAi should phenocopy the 
expression of Vpx, and consequently render cells more permissive to infection. Laguette and 
colleagues showed that siRNAs directed against SAMHD1 indeed were able to render dendritic cells 
between 6- and 34-fold more sensitive to infection by various HIV-1-derived lentiviral vectors. 
Furthermore, overexpression of an siRNA-resistant cDNA of SAMHD1 restored the restriction 
phenotype [30]. Hrecka et al. found that siRNAs against SAMHD1 had a modest depletion effect, 
possibly indicating that SAMHD1 protein has a long half-life, and resorted to a two-step strategy for 
depletion of SAMHD1. In the first step, pre-existing SAMHD1 protein would be degraded via VLP 
delivery of Vpx. Four days later, cells were transfected with SAMHD1 specific siRNAs, in order to 
prevent  de novo synthesis. This combined approach achieved the desired effect, and rendered 
macrophages sensitive to infection by HIV-1, SIVmac and HIV-2 [29]. 
As mentioned above, previous work had shown that Vpx-defective SIVmac and HIV-2 viruses, or 
HIV-1, when infecting dendritic cells, exhibited a defect in synthesis of late reverse transcripts, while a 
similar defect was not present in the synthesis of early reverse transcripts. Therefore, the expectation 
was that depletion of SAMHD1 would restore efficient synthesis of late reverse transcripts. 
Laguette et al. found that infection with an HIV-1-luciferase virus led to 13-fold higher levels of viral 
DNA accumulation in SAMHD1-silenced THP-1 cells when compared to control (scrambled siRNA) 
treated cells [30]. Hrecka et al. performed a more detailed reverse transcription analysis and 
demonstrated that, as expected, the presence of SAMHD1 in retroviral infection correlated with a 
selective decrease in the levels of late reverse transcripts but not of early ones. Furthermore, this effect 
was progressively attenuated with increasingly more effective SAMHD1-depleting treatments 
(a combination of VLP-Vpx delivery and siRNA) [29].  
3. SAMHD1 and the Aicardi-Goutières Syndrome  
The human SAMHD1 open reading frame was first identified in a cDNA library prepared 
in  MDDC, as being the homolog of the mouse gene, MG11, which is inducible by IFN- in 
MDM [31,32]. The new gene was then termed DCIP for dendritic cell-derived interferon- induced 
protein [31].  
SAMHD1’s HD domain is predicted to coordinate divalent-cations via two His (H) and two Asp 
(D) residues with variable spacing (H…DH…D) [33]. The HD domain is typically present in 
phosphohydrolases that can carry out phosphomonoesterase and phosphodiesterase activities [34]. The 
substrates for all studied HD domain proteins, with one exception, are nucleotides [33]. The E. coli 
YfbR protein for example, is an HD domain-containing enzyme that converts dNMPs to nucleosides 
and inorganic phosphate, thus controlling intracellular levels of nucleotides [33]. The exception is the 
YhaM protein from Bacillus subtilis, which has exoribonuclease activity [35]. Although the enzymatic 
activity of the SAMHD1 HD domain is not know at this time, when Laguette et al. mutated the 
canonical residues H and D to A and A, respectively, the resultant SAMHD1(HD/AA) was unable to Viruses 2011, 3                  
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induce restriction toward HIV-1 [30]. Therefore, the putative phosphohydrolase or exonuclease 
activity of the HD domain appears to be required for restriction.  
The sterile alpha motif (SAM) is a 65–70 amino acid residue domain that has been implicated in 
protein-protein interactions [36] and, in one specific instance, in binding to RNA hairpins [37]. 
Rice et al. investigated the possibility that the SAM domain of SAMHD1 could interact with RNA 
hairpins by surface plasmon resonance and by in-silico modeling based on the available structure 
SAMHD1’s SAM domain, and obtained negative results [38]. This would suggest that SAMHD1’s 
SAM mediates interaction with another protein. 
The gene encoding SAMHD1 is best known in the context of Aicardi-Goutières syndrome (AGS), a 
rare genetic disorder that causes encephalopathy and other sequelae that have striking resemblance to 
congenital infection and to some aspects of systemic lupus erythematosus (reviewed in [39]). The 
effector mechanism in the above diseases appears to be a type-I IFN-mediated innate immune response 
triggered by the presence of viral or host nucleic acids. AGS is genetically heterogeneous, with five 
loci (AGS1-5) so far having been identified as responsible for this syndrome when mutated. AGS1-4 
were identified as the (TREX1), RNASEH2B, RNASEH2C, RNASEH2A, respectively [39]. In 2009, 
AGS5 was identified as the gene encoding SAMHD1 [38].  
How the genes involved in AGS participate in its pathology is not well known. However, because 
TREX1 and RNASEH2 possess nucleolytic activity, it has been proposed that they participate in 
removing nucleic acids that may represent waste or the product of reverse transcription of transposable 
elements [40,41]. When these unwanted or aberrant nucleic acids are not cleared, they are thought to 
trigger a cell intrinsic type I IFN response. It is interesting to note that TREX1 has previously been 
implicated in the HIV-1 life cycle [42], although in a somewhat different manner to what Stetson et al. 
observed in the context of transposable elements [41]. Yan et al. proposed that TREX1 suppressed a 
type I IFN response that otherwise would be induced by HIV-1 infection [42]. TREX1 was proposed to 
degrade cytosolic DNA resulting from HIV-1 reverse transcription, which would otherwise be capable 
of inducing an IFN response [42]. 
4. Yet Another Restriction  
Manel and co-workers investigated the fate of viral infection in the presence or absence of the 
myeloid cell restriction and, specifically, whether any antiviral signaling was triggered when 
restriction was surpassed [21]. When restriction was overcome via VLP pre-delivery of Vpx, HIV-1 
infection triggered a potent type I IFN response that was dependent on de novo viral gene expression. 
Pertel and colleagues in a separate study also analyzed the properties of the IFN-induced inhibition of 
viral infection in MDDC, to find that VLP-delivered Vpx could overcome a potent block to HIV-1 
infection, which was derived from type I IFN stimulation [43]. This block resulted, presumably, from 
activation of the same “cryptic sensor” reported by Manel et al. [21], and it did not appear to have the 
properties of the block imposed by SAMHD1. Instead, this type-I IFN-derived restriction became 
active only if infection was successful beyond SAMHD1’s restricting ability. There were several 
surprises in the Pertel study. First, relief of the HIV-1 block by Vpx was DCAF1-independent [43]. 
Thus, Vpx mutants devoid of DCAF1 binding (such as Q76A and R80F) exerted similar relief of 
restriction as wild-type Vpx. Also, Vpx effectively relieved restriction in the face of RNAi-mediated Viruses 2011, 3                  
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depletion of DCAF1 [43]. The second surprise in the studies by Pertel et al. was that Vpx, while able 
to render MDDC cells permissive to HIV-1 infection, failed to relieve the potent block on SIVmac and 
HIV-2 induced by IFN stimulation [43]. Triggering of this response required viral gene expression, 
specifically, Gag protein [43]. Therefore, two new levels of restriction are emerging in myeloid cells, 
which act sequentially. The first level of restriction limits infection at an early step of the viral life 
cycle (reverse transcription) and is effected by SAMHD1. Vpx can overcome SAMHD1 restriction via 
recruitment of Cul4A
DDB1/DCAF1. A second level of restriction is triggered at a late stage in the viral life 
cycle and by an unknown sensor, and results in a potent type-I IFN response that very much resembles 
the response triggered by certain toll-like receptors. Vpx can help HIV-1 overcome this late response, 
but, paradoxically, is unable to facilitate infection by the cognate viruses, SIVmac and HIV-2. 
Finally, it is worth mentioning here that APOBEC3A has been found to inhibit infection of myeloid 
cells by alpharetroviruses [44], and by lentiviruses, such as HIV-1 and SIVmac/HIV-2 [45,46]; and 
that Vpx compromised the stability of APOBEC3A [45,46]. The antiviral activity of APOBEC3A, 
however, appears to reveal a different type of restriction from that imposed by SAMHD1. Key 
differences are that APOBEC3A expression is upregulated by HIV-1 infection although in a type I 
IFN-independent fashion [45]; and that Vpx-induced degradation of APOPBEC3A, although sensitive 
to the proteasome inhibitor MG132, does not appear to require the presence of DCAF1 [45].  
5. Conclusions and Future Directions  
SAMHD1 represents a novel type of restriction factor, which is specific to cells of the myeloid 
lineage. Whether SAMHD1 acts as a sensor, which can then transmit an alarm signal to activate an 
effector mechanism, or whether it acts as an effector remains to be elucidated. SAMHD1 alone does 
not explain some discrepancies between cell type distribution and its ability to restrict viral infection. 
Therefore, it is anticipated that additional requirements for antiviral activity will soon emerge. 
Overcoming SAMHD1 and allowing viral integration and gene expression was observed to elicit a 
potent IFN response with properties that were different from those of SAMHD1-mediated restriction. 
Thus, it is also anticipated that further studies will eventually reveal the nature of the “cryptic sensor” 
present in dendritic cells.  
Collectively, many studies are now highlighting an important difference in the pathogenesis 
between HIV-1 and that of HIV-2/SIVmac. It appears that HIV-2 and SIVmac have evolved 
mechanisms to overcome restriction in dendritic cells and macrophages, and can therefore efficiently 
infect such cell types. It is intriguing that HIV-1 can be targeted by the same restrictions and, 
consequently perhaps, HIV-1 infects macrophages inefficiently and does not infect dendritic cells. 
HIV-1 has not evolved, it seems, counteracting mechanisms that parallel the role of Vpx, but can 
clearly benefit from the ectopic expression of Vpx in myeloid cells. 
Sound scientific discoveries raise more questions than those for which they provide answers. The 
identification of SAMHD1 as a myeloid cell restriction factor is undoubtedly in that category.  
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